BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

Sarepta Therapeutics

Sarepta Therapeutics logo

Founded
1980
Patents
52
Clinical Trials
32
Publications
52

Sarepta Therapeutics – formerly AVI BioPharma – remains focused on developing first-in-class, RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. Sarepta’s unique technology has yielded a diverse pipeline of RNA-based therapeutics that include their lead clinical candidate, eteplirsen, for the treatment of Duchenne muscular dystrophy, a debilitating and life-threatening genetic disorder, as well as potential treatments for some of the world’s most lethal infectious diseases.